WallStreetZenWallStreetZen

NASDAQ: CPRX
Catalyst Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Catalyst Pharmaceuticals earnings were $214.3M for the trailing 12 months ending Dec 31, 2025, with 26.8% growth year over year. The latest CPRX earnings report on Dec 31, 2025 announced Q4 2025 earnings of $52.7M, down 0.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, CPRX reported annual earnings of $214.3M, with 30.8% growth.

CPRX past earnings growth

How has CPRX's earnings growth performed historically?

Company
26.81%
Industry
82.05%
Market
88.33%
CPRX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
CPRX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
CPRX's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

CPRX earnings history

Current Revenue
$589.0M
Current Earnings
$214.3M
Current Profit Margin
36.4%

CPRX Return on Equity

Current Company
24.3%
Current Industry
-10.9%
Current Market
29.5%
CPRX's Return on Equity (24.3%)... subscribe to Premium to read more.
High Return on Equity Performance

CPRX Return on Assets

Current Company
21.2%
Current Industry
-7.4%
CPRX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when CPRX announces earnings.

CPRX Return on Capital Employed

Current Company
29.63%
Current Industry
-1.8%
CPRX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CPRX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
CPRX$321.68M$214.33M+19.44%$1.75
TNGX-$95.35M-$101.59MN/A-$0.87
RCUS-$328.00M-$353.00MN/A-$3.29
TARS-$52.93M-$66.42MN/A-$1.59
ARQT$1.78M-$16.14MN/A-$0.13
View Top Biotech Stocks

Catalyst Pharmaceuticals Earnings Reports & History FAQ

What were Catalyst Pharmaceuticals's earnings last quarter?

On CPRX's earnings call on Invalid Date, Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 2025 earnings per share (EPS) of $0.43, up 6.52% year over year. Total CPRX earnings for the quarter were $52.70 million. In the same quarter last year, Catalyst Pharmaceuticals's earnings per share (EPS) was $0.46.

If you're new to stock investing, here's how to buy Catalyst Pharmaceuticals stock.

Is Catalyst Pharmaceuticals profitable or losing money?

As of the last Catalyst Pharmaceuticals earnings report, Catalyst Pharmaceuticals is currently profitable. Catalyst Pharmaceuticals's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $214.33 million, a 30.78% increase year over year.

What was CPRX's earnings growth in the past year?

As of Catalyst Pharmaceuticals's earnings date in Invalid Date, Catalyst Pharmaceuticals's earnings has grown 26.81% year over year. This is 55.24 percentage points lower than the US Biotechnology industry earnings growth rate of 82.05%. CPRX earnings in the past year totalled $214.33 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.